Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial

Clin Trials. 2009 Dec;6(6):618-27. doi: 10.1177/1740774509348525. Epub 2009 Nov 4.

Abstract

Background: Even though adverse event (AE) collection and official accounting are mandatory for clinical trials, there are limited detailed guidelines specifying how to summarize the event for reporting in a timely and expeditious manner. This article details the AE and serious adverse event (SAE) reporting summary developed for a large multi-center National Institutes of Health (NIH)-sponsored clinical trial.

Purpose: To review and analyze the large volume of AE data reported by 10 sites (806 SAEs and 19,034 AEs from August 2000 to May 2007) the automated SAE summary was developed. It was designed to ensure timeliness and clarity in the complex process of AE review and reporting.

Methods: The AE and SAE case report forms (CRFs) as well as the automated SAE summary were developed within a database management system developed by the Data Coordinating Center (DCC) which allowed for web-based data entry at the DCC and 10 sites and offered immediate overall and site-specific reports accessible by the DCC, site, and NIH project staff.

Results: The automated SAE summary pulled data from multiple CRFs to create a succinct and informative summary and allowed for prompt and easy reporting to the regulatory agencies. The summary was adaptable to the needs of reviewers because of the availability of multiple search options.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adverse Drug Reaction Reporting Systems / organization & administration*
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular / etiology
  • Carcinoma, Hepatocellular / prevention & control
  • Database Management Systems
  • Disease Progression
  • Electronic Data Processing / methods*
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / mortality
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / prevention & control
  • Liver Failure / etiology
  • Liver Failure / prevention & control
  • Liver Neoplasms / etiology
  • Liver Neoplasms / prevention & control
  • Multicenter Studies as Topic / methods
  • National Institutes of Health (U.S.)
  • Polyethylene Glycols / adverse effects*
  • Polyethylene Glycols / therapeutic use
  • Randomized Controlled Trials as Topic / methods*
  • Recombinant Proteins
  • Research Design
  • United States

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2a

Grants and funding